Oligosaccharide Replacement of a Therapeutic Antibody by using Endo-M and Glycosynthase
As a result of chemoenzymatic glycoengineering, multi-form N-linked oligosaccharides of a therapeutic antibody were replaced by the structure fine-defined oligosaccharide
In recent years, the expectation of a therapeutic benefit for antibody drugs is growing and the development of industrial technology for antibody production is required. However, heterogeneity of glycosylation of antibody drugs has long been left unsolved.
In this context, TCI achieved introduction of a MONO-form oligosaccharide to a defucosylated therapeutic antibody by using our enzyme products, “Endo-M” and “Glycosynthase”.
1. Verification of enzymatic reaction
After coupling of a MONO-form oligosaccharide to the Endo-M-treated antibody, a peak shift of the H chain of the therapeutic antibody was observed while a peak shift of L chain was not.
2. Detection of sialylated oligosaccharide
After coupling of a MONO-form oligosaccharide to the Endo-M-treated antibody, a band shift of the H chain of the therapeutic antibody was observed while a band shift of L chain was not.
B) Lectin blotting
In this study, SSA (Sambucus sieboldiana agglutinin) was used. A band of H chain of the therapeutic antibody coupled with MONO-form oligosaccharide was significantly stained.
M. Umekawa, T. Higashiyama, T. Tanaka, M. Noguchi, A. Kobayashi, S. Shoda, W. Huang, L-X. Wang, H. Ashida, K. Yamamoto, Biochim. Biophys. Acta, Gen. Subj. 2010, 1800, 1203.
M. Umekawa, C. Li, T. Higashiyama, W. Huang, H. Ashida, K. Yamamoto, L-X. Wang, J. Biol. Chem. 2010, 285, 511.